Epigenetics Diagnostic Market Size, Share, Trends, Growth and Forecast 2032

Epigenetics Diagnostic Industry Prospective:

The global epigenetics diagnostic market size was evaluated at $13.75 billion in 2023 and is slated to hit $58.75 billion by the end of 2032 with a CAGR of nearly 19% between 2024 and 2032.

Request Free Sample  

Epigenetics Diagnostic Market: Overview

Epigenetics diagnostic is an evolving field that uses epigenetic markers, including histone modifications and DNA methylation, to identify disorders such as cancer, autoimmune disorders, and neurodegenerative ailments. Reportedly, by evaluating epigenetic markers, researchers can detect chronic diseases in an early phase and develop targeted treatments for them.

Key Insights

• As per the analysis shared by our research analyst, the global epigenetics diagnostic market is projected to expand annually at the annual growth rate of around 19% over the forecast timespan (2024-2032)
• In terms of revenue, the global epigenetics diagnostic market size was evaluated at nearly $13.75 billion in 2023 and is expected to reach $58.75 billion by 2032.
• The global epigenetics diagnostic market is anticipated to grow rapidly over the forecast timespan owing to an increase in chronic disorders such as Parkinson's, Alzheimer’s, and rheumatoid arthritis.
•  In terms of product, the kits & reagents segment is slated to register the highest CAGR over the forecast period.
•  Based on application, the oncology segment is predicted to record immense growth in the upcoming years.
• On the basis of technology, the next-generation sequencing segment will record the highest gains in the coming years
•  In terms of end-user, the academic & research institutes segment is expected to propel the industry growth in the coming years.
• Region-wise, the European epigenetics diagnostic industry is projected to register the fastest CAGR during the projected timespan.

Epigenetics Diagnostic Market: Growth Factors

A surge in chronic diseases will proliferate the global market demand over forecast period

An increase in chronic disorders such as Parkinson's, Alzheimer’s, and rheumatoid arthritis is likely to expand the scope of the global epigenetics diagnostic market demand. Apart from this, breakthroughs in biotech, such as next-generation sequencing and epigenetic profiling methods, can further augment the global market surge.

Additionally, an increase in the allocation of funds to research activities in the pharma sector and academic institutes is likely to proliferate the expansion of the global market.

Epigenetics Diagnostic Market: Restraints

Surging prices of new systems can restraint the global industry expansion over forecast period

A rise in the costs of advanced technologies and a scarcity of skilled professionals are a few of the major factors affecting the growth of the global epigenetics diagnostic market. Furthermore, growing costs of testing along with low standardization assays can severely impact the growth of the global industry. Surging privacy concerns and technical challenges can deter the global industry surge in the ensuing years.

Epigenetics Diagnostic Market: Opportunities

Launch of new treatment modes can open new growth facets for global market over analysis timeline

Growing demand for precision medicine and early disease identification can open new growth avenues for the global epigenetics diagnostic industry. Moreover, new drug discovery and development are likely to generate new facets of growth for the global market.

Epigenetics Diagnostic Market: Challenges

Stringent regulations regulating use of epigenetics diagnostics can challenge the global industry surge by 2032

Complexities witnessed in the epigenetic mechanism along with data analysis challenges can obstruct the expansion of the global epigenetics diagnostic industry. Moreover, strict laws governing the use of epigenetics diagnostics will challenge the global industry surge in the years ahead.    

Epigenetics Diagnostic Market: Segmentation

The global epigenetics diagnostic market is divided into product, application, technology, end-user, and region.                                             

In terms of product, the epigenetics diagnostic market across the globe is segmented into kits & reagents, software & services, and instruments segments. Apparently, the kits & reagents segment, which amassed nearly 55% of the global market revenue in 2023, is anticipated to record the fastest CAGR in the coming seven years due to their user-friendly features, cost-efficiency, and versatility.

Based on the application, the global epigenetics diagnostic industry is segmented into oncology, autoimmune disorders, and neurological disorders segments. Apparently, the oncology segment, which accounted majorly to the global industry revenue in 2023, is anticipated to register lucrative growth in the ensuing years. This can be credited to major health concerns, the need for precision medicine, and drug development.

On the basis of technology, the global epigenetics diagnostic market is divided into histone modification analysis, next-generation sequencing, DNA methylation analysis, and chromatin immunoprecipitation segments.

Moreover, the next-generation sequencing segment, which contributed sizably towards the global market size, is expected to account for the highest gains in the coming eight years owing to its ability to offer high throughput analysis, specificity, and versatility.

Based on the end-user, the epigenetics diagnostic industry across the globe can be segmented into pharmaceutical & biotechnology firms, academic & research institutes, and clinical diagnostic laboratories segments. Moreover, the academic & research institutes segment, which accounted lucratively towards the global market share in 2023, is anticipated to propel the global industry growth in the coming years. The segmental surge in the coming eight years can be due to an increase in the allocation of funds for research activities.

Epigenetics Diagnostic Market: Report Scope

Epigenetics Diagnostic Market: Regional Insights

North America is likely to maintain leading status in the global market over the analysis timeline

North America, which contributed about 45% of the global epigenetics diagnostic market earnings in 2023, is expected to establish a leading position in the global market in the coming few years.

Additionally, the regional market progression in the next couple of years can be credited to upgraded healthcare systems, the presence of robust research infrastructure, and a rise in the government funding of diagnostics centers. Presence of key market players in countries such as Canada and the U.S. will drive the regional market trends.

The European epigenetics diagnostic industry is likely to record the fastest compound annual growth rate in the forecast timeline. The elevation of the industry in Europe can be a result of supportive government schemes along with early acceptance of new systems. Apart from this, the presence of effective healthcare amenities and biotech firms in Germany, Russia, Finland, the UK, and France will embellish the industry surge in Europe.  

Key Developments

• In April 2019, Greenwood Diagnostic Laboratories signed an agreement with the London Health Sciences Center to launch a novel diagnostic test highlighting disease-specific epigenetic signatures.
• In February 2024, Wasatch Biolabs introduced a targeted DNA methylation sequencing service for healthcare providers and researchers.

Epigenetics Diagnostic Market: Competitive Space

The global epigenetics diagnostic market profiles key players such as:

• Epigentek Group
• Agilent Technologies Inc.
• Element Biosciences Inc.
• Roche Diagnostics
• Illumina Inc.
• Eisai Co. Ltd.
• Thermo Fisher Scientific Inc.
• Novartis AG
• Merck KGaA
• Abcam plc
• Dovetail Genomics LLC
• Zymo Research Corporation
• Diagenode
• Active Motif Inc.

The global epigenetics diagnostic market is segmented as follows:

By Product

• Kits & Reagents
• Software & Services
• Instruments

By Application

• Oncology
• Autoimmune Disorders
• Neurological Disorders

By Technology

• Histone Modification Analysis
• Next-Generation Sequencing
• DNA Methylation Analysis
• Chromatin Immunoprecipitation

By End-User

• Pharmaceutical & Biotechnology firms
• Academic & Research Institutes
• Clinical Diagnostic Laboratories

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa